Connect with us

Hi, what are you looking for?

Jewish Business News


Alcobra Raises $33 Million In Secondary Nasdaq Offering

The ADHD treatment developer raised $27 million in its IPO in May.




Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD) raised a gross $33 million in its secondary offering on Thursday. The company issued two million shares at $16.50 per share. The underwriters, Stifel Nicolaus, Aegis Capital Corp., JMP Securities have a 30-day option to buy additional 300, 000 sharesAlcobra will use the proceeds for the development of its proprietary drug, MG01CI (Metadoxine extended-release), for the treatment of ADHD and Fragile X Syndrome, a factor in autism.

Alcobra raised $27 million in its IPO in May.

Alcobra’s share price closed at $17.01 on Friday, giving a market cap of $189 million, after falling 0.5% during the session.


Published by 

1 Comment

1 Comment

  1. edwartfruitman

    March 12, 2015 at 8:22 am

    With the rapid increase in cases of ADHD, this issue has
    become more of a health crisis. Many psychiatrist
    and pharmaceutical companies are working together to find a lasting solution
    for this drastic mental disorder.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


Now Platika joins and elite club of $10 billion plus Israeli firms.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...